Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

KalVista Pharmaceuticals (KALV) Long-Term Debt Repayments (2018 - 2020)

KalVista Pharmaceuticals recorded quarterly Long-Term Debt Repayments of $1000.0 in Q2 2020, up 200.0% quarter-over-quarter from -$1000.0 in Q1 2020, and down 98.15% year-over-year from $54000.0 in Q2 2019.

KalVista Pharmaceuticals' Long-Term Debt Repayments history runs 3 years deep, the most recent figure standing at $1000.0 for Q2 2020.

  • In Q2 2020, Long-Term Debt Repayments fell 98.15% year-over-year to $1000.0; the TTM figure through Apr 2020 stood at $54000.0 (down 74.16% YoY), while the FY2020 annual figure was $54000.0, down 74.16% from the prior year.
  • Long-Term Debt Repayments came in at $1000.0 for Q2 2020 at KalVista Pharmaceuticals, up from -$1000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $54000.0 in Q2 2019 to a low of -$1000.0 in Q1 2020.
  • A 3-year average of $40555.6 and a median of $52000.0 in 2018 frame the typical range for Long-Term Debt Repayments.
  • Across the five-year window, Long-Term Debt Repayments increased 8.0% in 2019 and tumbled 101.96% in 2020, its largest moves.
  • KalVista Pharmaceuticals' Long-Term Debt Repayments stood at $52000.0 in 2018, then gained by 3.85% to $54000.0 in 2019, then sank by 98.15% to $1000.0 in 2020.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods registered $1000.0, -$1000.0, and $54000.0 for Q2 2020, Q1 2020, and Q3 2019 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 KalVista Pharmaceuticals 1.44 Bn 1.25 Bn 56.41 Mn -

Historic Data

Download Data 🔒
DateValue
Apr 30, 2020 1,000.00
Apr 30, 2020 1,000.00
Jan 31, 2020 -1,000.00
Jan 31, 2020 -1,000.00
Jul 31, 2019 54,000.00
Jul 31, 2019 54,000.00
Apr 30, 2019 54,000.00
Apr 30, 2019 54,000.00
Jan 31, 2019 51,000.00
Jan 31, 2019 51,000.00
Oct 31, 2018 52,000.00
Oct 31, 2018 52,000.00
Jul 31, 2018 52,000.00
Jul 31, 2018 52,000.00
Apr 30, 2018 50,000.00
Apr 30, 2018 50,000.00
Jan 31, 2018 52,000.00
Jan 31, 2018 52,000.00